Expanding the business and earnings platforms through acquisitions and integration

「As part of strengthening medical products, which we have positioned as a growth field, our Group is accelerating growth in the medical product wholesale business by strengthening its nationwide network through organizational restructuring, including alliances, management integration and business acquisitions.」

「We are also considering using this solution for Home Care Delivery※5, a special home-delivery service for patients receiving specialty pharmaceuticals operated by アルフレッサ.」

「In March 2026, we acquired all shares of Techno-Suzuta Co., Ltd. (Head office: Nagasaki City, Nagasaki Prefecture), a wholly owned subsidiary of 温仙堂 (Head office: Isahaya City, Nagasaki Prefecture) and a specialist trading company for clinical and research diagnostic reagents and medical devices, and made it a wholly owned subsidiary.」

「In September 2025, as part of efforts to strengthen its nationwide network in the medical equipment field, ティーエスアルフレッサ株式会社 acquired all shares of 株式会社ミヤノメディックス (head office: Fukuyama, Hiroshima), a specialist medical equipment wholesaler, making it a subsidiary. 東北アルフレッサ株式会社 also entered into a share transfer agreement to acquire all shares of 東日本メディカルシステム株式会社 (head office: Aoba, Sendai), another specialist medical equipment wholesaler (acquisition completed on 31 October).」

「Furthermore, in September 2024, we acquired all shares of ArkMS Co., Ltd. (head office: Toshima-ku, Tokyo), a newly established company formed through a company split involving Intage Healthcare Inc. (head office: Chiyoda-ku, Tokyo) in relation to its CRO and PMS businesses.」

「In September 2023, the Company acquired all shares of 有限会社会営, which operates prescription pharmacies including the カイエー薬局グループ in Saitama Prefecture, making it a wholly owned subsidiary. The Company continues to pursue the establishment of a dominant regional presence in home healthcare.」

「In February 2023, we acquired all shares of 宮崎温仙堂商店株式会社 from 温仙堂株式会社, making it a wholly owned subsidiary. Through this transaction, we will seek to strengthen our business foundation in the Kyushu area.」

「In December 2022, アルフレッサ ファーマ and サンノーバ株式会社 entered into an absorption-type merger agreement, under which アルフレッサ ファーマ would be the surviving company, effective 1 April 2023.」

「In May 2022, consolidated subsidiaries アルフレッサ ファーマ株式会社 (head office: Chuo-ku, Osaka; hereinafter “アルフレッサ ファーマ”) and サンノーバ株式会社 (head office: Ota, Gunma) reached a basic agreement on a merger by absorption, with アルフレッサ ファーマ as the surviving company, and aim to complete the integration in April 2023.」

「In May 2022, consolidated subsidiaries アルフレッサ ファーマ株式会社 (head office: Chuo-ku, Osaka) and サンノーバ株式会社 (head office: Ota, Gunma) reached a basic agreement on a merger by absorption, with アルフレッサ ファーマ株式会社 as the surviving company.」

「In addition, our company and our consolidated subsidiary アルフレッサ (head office: Chiyoda-ku, Tokyo; hereinafter “アルフレッサ”) agreed with しんようフォレストホールディングス (head office: Isahaya, Nagasaki Prefecture) and its wholly owned subsidiary 宮崎温仙堂商店 (head office: Isahaya, Nagasaki Prefecture) to begin discussions toward a capital and business alliance, with the aim of enhancing corporate value by strengthening the business base in Kyushu and improving our ability to respond to large-scale disasters and other events.」

「In January 2021, the consolidated subsidiary アルフレッサ ヘルスケア株式会社 and its wholly owned subsidiary 株式会社茂木薬品商会 entered into an absorption-type merger agreement under which アルフレッサ ヘルスケア株式会社 would be the surviving company, and the merger was completed on 1 April of the same year.」

「In January 2021, the consolidated subsidiary アルフレッサ ヘルスケア株式会社 (head office: Chuo, Tokyo) and its wholly owned subsidiary 株式会社茂木薬品商会 (head office: Chuo, Tokyo) entered into a merger agreement in which アルフレッサ ヘルスケア株式会社 would be the surviving company (effective date: 1 April 2021).」

「In October 2020, the consolidated subsidiary アポロメディカル, 株式会社日本アポック and the Company's wholly owned subsidiary 株式会社中日ファーマシー, which operates the prescription pharmacy business, reached a basic agreement on a merger in which アポロメディカル would be the surviving company.」

「In June 2020, for the purpose of strengthening the foundations and governance of the healthcare-related business (prescription pharmacy business), the company acquired additional shares in its consolidated subsidiary アポロメディカルホールディングス株式会社 (head office: Toshima-ku, Tokyo, hereinafter “アポロメディカル”), making it a wholly owned subsidiary.」

「On 1 October 2018, the business was integrated through a merger with 株式会社小田島, giving rise to 東北アルフレッサ株式会社. In addition, アルフレッサ篠原化学株式会社, a subsidiary whose operating base is the Shikoku region, became a consolidated subsidiary from the current consolidated fiscal year.」

「In addition, アルフレッサ篠原化学株式会社 (head office: Kochi, Kochi), a subsidiary whose operating base is the Shikoku region, became a consolidated subsidiary from the current consolidated fiscal year.」

「On 1 October 2018, 株式会社恒和薬品 and 株式会社小田島 integrated their businesses through a merger, launching 東北アルフレッサ株式会社 (head office: Koriyama, Fukushima). In addition, アルフレッサ篠原化学株式会社, a subsidiary whose operating base is Kochi Prefecture, became a consolidated subsidiary from the current fiscal year.」

「In July 2018, 株式会社恒和薬品 (head office: Koriyama, Fukushima) transferred its wholesale business for ethical pharmaceuticals and other products in Hokkaido to アルフレッサ株式会社 (head office: Chiyoda, Tokyo). In October 2018, 株式会社恒和薬品 and 株式会社小田島 (head office: Hanamaki, Iwate) were scheduled to merge and integrate all their businesses, launching 東北アルフレッサ株式会社 (head office: Koriyama, Fukushima). In addition, the subsidiary アルフレッサ篠原化学株式会社 (head office: Kochi, Kochi), whose operating base is Kochi Prefecture, became a consolidated subsidiary from the first quarter of the current fiscal year.」

「In October 2017, our consolidated subsidiary 株式会社日本アポック (head office: Kawagoe, Saitama) merged with our non-consolidated subsidiary 株式会社ユースケア.」

「In October 2017, the Company's consolidated subsidiary 株式会社日本アポック merged 株式会社ユースケア, a non-consolidated subsidiary of the Company.」

「In July 2017, the Company's wholly owned subsidiary 株式会社日本アポック (head office: Kawagoe, Saitama) and 株式会社ユースケア (head office: Chiyoda, Tokyo) entered into a merger agreement, with 1 October 2017 scheduled as the effective date.」

「In October 2016, アルフレッサ株式会社 (head office: Chiyoda, Tokyo), the Company's consolidated subsidiary, merged シーエス薬品株式会社 (head office: Naka, Nagoya), a consolidated subsidiary operating in the Tokai region. The Company aims to further strengthen its community-based sales platform by using management resources effectively and efficiently.」

「In July 2016, アルフレッサ株式会社 (head office: Chiyoda, Tokyo) integrated the wholesale business for ethical pharmaceuticals and other products operated by ティーエスアルフレッサ株式会社 in the Kyushu area. In October of the same year, it was also scheduled to merge シーエス薬品株式会社 (head office: Naka, Nagoya), whose operating area was the Tokai region.」

「In April 2015, the 2 wholly owned subsidiaries 成和産業株式会社 and 常盤薬品株式会社 were integrated, and operations began under the name ティーエスアルフレッサ株式会社 (head office: Nishi, Hiroshima).」